Hims & Hers Health (HIMS)
NYSE:HIMS
HIMS Stock Chart & Stats
$19.43
-$0.61(-2.20%)
At close: 4:00 PM EST
$19.43
-$0.61(-2.20%)
Day’s Range― - ―
52-Week Range$13.74 - $70.43
Previous CloseN/A
Volume4.28M
Average Volume (3M)37.28M
Market Cap
$4.43B
Enterprise Value$5.30B
Total Cash (Recent Filing)$577.49M
Total Debt (Recent Filing)$1.26B
Price to Earnings (P/E)56.9
Beta2.35
Next Earnings
May 11, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.08
Shares Outstanding219,561,140
10 Day Avg. Volume19,570,428
30 Day Avg. Volume37,276,550
Financial Highlights & Ratios
PEG Ratio-33.00
Price to Book (P/B)13.50
Price to Sales (P/S)3.11
P/FCF Ratio98.76
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue2.26
Enterprise Value/Gross Profit3.06
Enterprise Value/Ebitda33.02
Forecast
1Y Price Target
$26.36Price Target Upside35.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)0.41
Revenue Forecast (FY)$2.76B
Bulls Say, Bears Say
Bulls Say
Affordability And Payment AccessEligibility to use health savings and flexible spending accounts for membership and medication costs improves affordability and could support broader adoption of branded treatments.
Branded Subscription EconomicsThe Novo partnership enables a premium branded weight-loss subscription that bundles medication with continuous provider access and wellness services, which could raise profit per subscriber if users convert from lower-priced alternatives.
Legal Risk ReductionNovo Nordisk dropping its lawsuit against Hims & Hers removes a major legal overhang and substantially reduces litigation and regulatory risk for the company.
Bears Say
Margin Pressure From Product ShiftShifting patients from higher-margin compounded therapies to branded medicines is likely to create a margin headwind as compounding economics are replaced and recent investments must be repurposed.
Regulatory And Enforcement RiskTightening guidance on mass compounding and referrals to law enforcement increase regulatory scrutiny, elevating legal and reputational risk for companies that rely on compounded drug offerings.
Revenue And EBITDA DownsideStopping mass marketing and winding down compounded GLP-1 sales is expected to cause a significant decline in reported revenue and adjusted EBITDA.
Hims & Hers Health News
HIMS FAQ
What was Hims & Hers Health’s price range in the past 12 months?
Hims & Hers Health lowest stock price was $13.74 and its highest was $70.43 in the past 12 months.
What is Hims & Hers Health’s market cap?
Hims & Hers Health’s market cap is $4.43B.
When is Hims & Hers Health’s upcoming earnings report date?
Hims & Hers Health’s upcoming earnings report date is May 11, 2026 which is in 28 days.
How were Hims & Hers Health’s earnings last quarter?
Hims & Hers Health released its earnings results on Feb 23, 2026. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.04.
Is Hims & Hers Health overvalued?
According to Wall Street analysts Hims & Hers Health’s price is currently Undervalued.
Does Hims & Hers Health pay dividends?
Hims & Hers Health does not currently pay dividends.
What is Hims & Hers Health’s EPS estimate?
Hims & Hers Health’s EPS estimate is 0.03.
How many shares outstanding does Hims & Hers Health have?
Hims & Hers Health has 219,561,140 shares outstanding.
What happened to Hims & Hers Health’s price movement after its last earnings report?
Hims & Hers Health reported an EPS of $0.08 in its last earnings report, beating expectations of $0.04. Following the earnings report the stock price went down -0.322%.
Which hedge fund is a major shareholder of Hims & Hers Health?
Currently, no hedge funds are holding shares in HIMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hims & Hers Health Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$26.36 (35.69% Upside)
$26.36 (35.69% Upside)
Blogger Sentiment
Bullish
HIMS Sentiment 87%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 7.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $414.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days <0.1%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Bearish
Bullish news 33%
Bearish news 67%
Bearish news 67%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.52%
12-Months-Change
Fundamentals
Return on Equity
22.99%
Trailing 12-Months
Asset Growth
197.28%
Trailing 12-Months
Company Description
Hims & Hers Health
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.
HIMS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and financial improvement: robust top-line growth (Q4 +28%, FY +59%), expanding profitability (adjusted EBITDA +~80%), growing subscriber base (>2.5M) and meaningful cash generation. Management emphasized rapid product launches, diagnostic and hormonal early successes, and aggressive international expansion via acquisitions. Offsetting these positives are near-term headwinds from fulfillment timing ($65M Q1 revenue timing impact), margin pressure from investments and international mix, regulatory uncertainty around compounded GLP-1s, and sizable acquisition-related commitments. Overall, fundamentals and strategic investments appear to outweigh the near-term risks, though execution and regulatory outcomes will be key to sustaining the trajectory.View all HIMS earnings summariesHIMS Revenue Breakdown
96.60% Online
3.40% Wholesale
HIMS Stock 12 Month Forecast
Average Price Target
$26.36
▲(35.69% Upside)
Technical Analysis
Ownership Overview
5.53% Insiders
23.06% Mutual Funds
0.07% Other Institutional Investors
51.48% Public Companies and Individual Investors